The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT radiopharmaceutical for the imaging of Non-muscle-invasive bladder cancer (NMIBC) patients.
There is a real need for treatment of NMIBC. Currently, treatment options include Bacillus Calmette-Guerin (BCG) intravesical immunotherapy and mitomycin C chemotherapy. These therapies are efficient for some time but relapses repeat them at more and more close intervals and finally patients are refractory to them and require a radical cystectomy. CAIX is expressed in 70% to 90% of bladder cancers but not in normal urothelial tissue. CAIX is expressed on the membrane of Non-Muscle-Invasive Bladder Cancer cells. Girentuximab, an anti-CAIX antibody could be a promising target in NMIBC. PET/CT with Girentuximab labelled with 89Zirconium will be used for diagnosis purpose. 89Zr-Girentuximab will be administered by intravesical instillation. In this study, patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) will be enrolled in this study after confirmation of their eligibility. A single intravesical administration of 89Zr-Girentuximab will be performed at day 0. Multiple PET/CT imaging sessions will be performed on day 0, day 1 and day 2 in order to evaluate the bladder and the whole body 89Zr girentuximab uptake.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
6
89Zr-TLX250 (89Zr-girentuximab) PET/CT performed for all aptients
Institut de cancerologie de l'Ouest
Saint-Herblain, France
Number of Participants With Uptake Spot in 89Zr-girentuximab PET/CT Images
The presence or absence of uptake spot in bladder wall of 89Zr-girentuximab bladder and whole body PET/CT Images.
Time frame: 3 days
Number of Patients With Positive and Negative 89Zr-girentuximab Blood Dosing
89Zr-girentuximab activity dosing in blood is measured. The number of patients with Positive and negative 89Zr-girentuximab Blood dosing is evaluated.
Time frame: 2 days
Number of Participants With Serious Adverse Events
Serious adverse events, related or not to 89Zr-girentuximab, are assessed up to Day 30 after 89Zr-girentuximab administration, using CTC-AE scale version 5.0
Time frame: 30 days
Number of Patients With Positive and Negative CA-IX Expression in Tumor Cells
The expression of CAIX is by immunohistochemistry in tumor sample from TransUrethral Resection of Bladder Tumor (TURBT) or cystectomy
Time frame: 3 months
Number of Participants With Adverse Events Related to 89Zr-girentuximab
Adverse events related to 89Zr-girentuximab are assessed up to Day 3 After 89Zr-girentuximab Administration, using CTC-AE scale version 5.0
Time frame: 3 days
Radiation Protection Management
Radiation exposure of 3 staff membres (extremities and Whole body: µSv). A value greater than 4mSv is considered abnormal.
Time frame: 3 days
Radiation Protection Management
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Radiopharmaceutical management from intravesical instillation to elimination (surfasic contamination measured in counts/second).
Time frame: 1 day